vida: extract claims from 2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025

- Source: inbox/queue/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md
- Domain: health
- Claims: 0, Entities: 2
- Enrichments: 1
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials.md

@@ -24,3 +24,10 @@ The EVOKE trials produced a striking disconnection: statistically significant 10
 **Source:** Exenatide-PD3 Phase 3 RCT, Lancet February 2025
 
 Exenatide Phase 3 showed no DaT-SPECT signal change versus placebo, meaning the biomarker tracking dopaminergic neuron degeneration showed zero neuroprotection. This directly confirms that biomarker improvement (or lack thereof) can fail to translate to clinical benefit in neurodegeneration trials. The Phase 2 motor benefit (P=0.001) did not replicate in Phase 3, suggesting the earlier biomarker signal was spurious or underpowered.
+
+
+## Extending Evidence
+
+**Source:** Holscher 2024 review + exenatide Phase 3 CSF data (Lancet Feb 2025)
+
+Exenatide Phase 3 CSF analysis revealed that BBB crossing (a pharmacokinetic surrogate) doesn't predict substantia nigra penetrance (the therapeutic target). Only small amounts reached affected brain areas despite documented BBB penetrance, explaining Phase 2 success (general neuroprotection) versus Phase 3 failure (insufficient regional delivery).

domains/health/glp1-neuroprotection-requires-regional-cns-penetrance-not-just-bbb-crossing.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: Exenatide's Phase 3 failure despite BBB penetrance reveals that general brain access differs from therapeutic delivery to specific affected structures
+confidence: experimental
+source: "Holscher 2024 review (Alzheimer's & Dementia), exenatide Phase 3 CSF analysis (Lancet 2025)"
+created: 2026-05-08
+title: GLP-1 neuroprotective effects in Parkinson's disease require regional CNS penetrance to the substantia nigra, not just blood-brain barrier crossing
+agent: vida
+sourced_from: health/2026-05-08-glp1-bbb-penetrance-neuroprotection-holscher-2024.md
+scope: causal
+sourcer: Holscher C.
+related: ["glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials", "glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure"]
+---
+
+# GLP-1 neuroprotective effects in Parkinson's disease require regional CNS penetrance to the substantia nigra, not just blood-brain barrier crossing
+
+Holscher's 2024 review proposed that GLP-1 agonists' neuroprotective effects correlate with blood-brain barrier penetrance, ranking drugs by BBB crossing ability. Exenatide and lixisenatide showed good BBB penetrance and positive Phase 2 results in Parkinson's disease, while liraglutide (limited BBB penetrance) and NLY01 (no BBB penetrance) showed limited or no effects. However, exenatide's Phase 3 failure in February 2025 revealed a critical distinction: CSF analysis showed that despite crossing the BBB, only small amounts of exenatide reached the substantia nigra specifically—the affected brain structure in Parkinson's. This creates a two-level pharmacokinetic model: (1) BBB penetrance determines general brain access, but (2) regional CNS penetrance determines therapeutic delivery to specific structures. The substantia nigra appears to require different pharmacokinetic properties than what BBB crossing alone predicts. This framework reconciles the divergent trial results: exenatide's Phase 2 success reflected BBB crossing, but Phase 3 failure reflected insufficient substantia nigra penetrance. Lixisenatide's continued Phase 2 success suggests it may achieve better regional penetrance despite similar BBB crossing mechanisms. Semaglutide's unique penetrance pathway (albumin binding → tanycytes → third ventricle wall) accesses different brain regions than passive diffusion, making its substantia nigra penetrance an open empirical question that will determine Phase 3 outcomes.

entities/health/nct-semaglutide-cud-phase2-cbt.md

@@ -0,0 +1,22 @@
+# Semaglutide + CBT for Cocaine Use Disorder (Phase 2)
+
+**Type:** Clinical trial  
+**Phase:** 2  
+**Status:** Recruiting (as of May 2026)  
+**Intervention:** Semaglutide combined with cognitive behavioral therapy (CBT)  
+**Population:** Adults with diagnosed cocaine use disorder and BMI ≥25  
+**Primary objective:** Reduce cocaine cravings and use  
+**Registry:** withpower.com/trial/phase-2-cocaine-related-disorders-10-2025
+
+## Timeline
+
+- **2025-10** — Trial opened for recruitment
+- **2026-05** — Actively recruiting participants
+
+## Context
+
+This trial follows the All of Us observational finding (Abegaz et al., March 2026) showing 75% lower odds of cocaine use disorder in GLP-1 users (OR=0.25). Cocaine use disorder has no FDA-approved pharmacotherapy, making this a high-priority unmet need. The trial combines semaglutide with CBT, reflecting the behavioral-biological integration model seen in other GLP-1 SUD trials.
+
+## Expected Results
+
+Phase 2 results anticipated 2027-2028.

entities/health/nct-semaglutide-cud-phase2-hiv.md

@@ -0,0 +1,23 @@
+# Semaglutide for Cocaine Use Disorder in HIV Cohort (Phase 2)
+
+**Type:** Clinical trial  
+**Phase:** 2  
+**Status:** Recruiting (as of May 2026)  
+**Intervention:** Semaglutide vs. placebo  
+**Population:** Adults with cocaine use disorder, with and without HIV infection  
+**Primary objective:** Safety and effectiveness of semaglutide for CUD  
+**Special population rationale:** High CUD prevalence in HIV+ individuals; dual metabolic and addiction benefits  
+**Registry:** withpower.com/trial/phase-2-human-immunodeficiency-virus-hiv-infections-2-2025
+
+## Timeline
+
+- **2025-02** — Trial opened for recruitment
+- **2026-05** — Actively recruiting participants
+
+## Context
+
+This trial targets a high-need population where CUD prevalence is elevated and metabolic complications are common. The HIV-specific design provides real-world justification for off-label use even before CUD-specific approval. Follows All of Us observational signal (OR=0.25 for CUD in GLP-1 users).
+
+## Expected Results
+
+Phase 2 results anticipated 2027-2028.

inbox/archive/health/2026-05-08-glp1-bbb-penetrance-neuroprotection-holscher-2024.md

@@ -7,10 +7,13 @@ date: 2025-01-01
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-08
 priority: medium
 tags: [GLP-1, blood-brain barrier, neuroprotection, Parkinson's disease, Alzheimer's disease, pharmacokinetics, CNS penetrance, semaglutide, exenatide, lixisenatide]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md

@@ -7,10 +7,13 @@ date: 2025-01-01
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-08
 priority: medium
 tags: [GLP-1, cocaine use disorder, substance use disorder, semaglutide, Phase 2 trial, addiction medicine, CUD]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content